This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

NovoSeven® is indicated for the treatment of bleeding  episodes and for the prevention of bleeding in surgery or  invasive procedures in patients with congenital haemophilia  with inhibitors to coagulation factors VIII or IX, congenital  haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII  deficiency, and Glanzmann’s thrombasthenia with past or  present refractoriness to platelet transfusions or where  platelets are not readily available.1

NovoSeven® is indicated for the treatment of severe  postpartum haemorrhage when uterotonics are insufficient  to achieve haemostasis.1,3

1.

NovoSeven® Summary of Product Characteristics. SFDA Label.

2.

Maahs J et al. J Blood Med. 2014;5:153–156.

3.

Committee for Medicinal Products for Human Use (CHMP), “CHMP extension of indication variation assessment report (NovoSeven®), `EPAR’”; 22 April 2022. Procedure No. EMEA/H/C/000074/II/0116.

4.

Hedner U. Blood Rev 2015;29(S1):S4–S8.

5.

Hemlibra® Summary of Product Characteristics.

6.

FEIBA® Summary of Product Characteristics.

7.

Baudo F et al. Blood 2012;120(1):39–46.

8.

Neufeld EJ et al. Blood Rev 2015;29(S1):S34–S41.

9.

Rexen P et al. TH Open 2019;3:e45–e49.

10.

Santagostino E et al. Thromb Haemost 2006;4(2):367–371.

11.

Neufeld EJ et al. Pediatr Blood Cancer 2013;60(7):1178–1183.

12.

Pruthi RK et al. Thromb Haemost 2007;98(4):726–732.

13.

Shapiro AD et al. Thromb Haemost 1998;80(5):773–778.

14.

Parameswaran R et al. Haemophilia 2005;11(2):100–106.

15.

Hay CR et al. Thromb Haemost 1997;7(8):1463–1467.

16.

Amano K et al. Haemophilia 2016;23(1):50–58.

17.

Borel-Derlon A et al. Haemophilia 2016;22 Suppl 4:3–138. Poster PO-W-4.

18.

Sumner MJ et al. Haemophilia 2007;13(5):451–461.

19.

Lentz SR et al. J Blood Med 2014;5:1–3.

20.

Sun B et al. Br J Haematol 2019. doi: 10.1111/bjh.16128.[Epub ahead of print].

21.

Pardos-Gea J et al. Haemophilia 2018;24(3):e163–e166.

22.

Tiede A, Worster A. Ann Hematol 2018;97(10):1889–1901.

23.

Abshire T, Kenet G. Haemophilia 2008;14(5):898–902.

24.

Pollard D et al. J Haem Pract 2017;4(1):1–5.

25.

Demartis F et al. TH Open 2017;1:e130–e138.

26.

Lentz SR et al. J Thromb Haemost 2014; 12(8):1244–1253.

27.

Di Minno G et al. Haematologica 2015;100(8):1031–7.

28.

Mariani G et al. Thromb Haemost 2013;109:238–247.

29.

Hoffman M Dargaud Y. J Thromb Haemost2012;10:1478–1485.

30.

Neufeld EJ et al.Haemophilia 2011;17:650–656.

31.

Neufeld EJ et al. Haemophilia 2018;24(4):e275–e277.